News Release

SOLVD Health CEO Named Clinical Scientist of the Year by the Association of Clinical Scientists

Dr. Keri Donaldson was recognized by his peers for his outstanding contributions to clinical science in research, teaching, and service.

CARLSBAD, Calif., June 1, 2021Keri Donaldson, MD, the CEO and founder of SOLVD Health, a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, was recently named Clinical Scientist of the Year by the Association of Clinical Scientists (ACS).

Each year, the Awards Committee selects a Fellow of the Association to receive the annual Sunderman Award, which is named in honor of Dr. F.W. Sunderman, Sr., the Association’s founder. The recipient is selected by their peers for making outstanding contributions to clinical science in research, teaching, and service, and is designated the Clinical Scientist of the Year.

Dr. Donaldson is the current president of ACS and has dedicated his medical career to improving people’s lives through advancements in pathology, genomics, and diagnostics. Prior to founding SOLVD Health, he directed numerous clinical laboratories and has held key positions within respected institutions including University of Pennsylvania, Penn State Health, and Temple University. In addition, he is active in numerous national committees and professional societies focused on improving diagnostic testing and patient care. He holds an MD from Temple University School of Medicine and a Master of Science in Clinical Epidemiology (MSCE) from the University of Pennsylvania School of Medicine.

ACS was formed in 1949 to promote education and research in clinical science. Overarching goals of the Association include improving laboratory testing and encouraging cooperation among health professionals in the application of scientific methods in clinical practice and research.

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, we are enabling individuals and their providers to make better decisions about their health and the health of their families. We accomplish this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about us, our solutions, and our career opportunities, visit us at www.solvdhealth.com.

Media Contact:
Valerie Melucci; pr@solvdhealth.com 

 

SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test

SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test

November 18, 2024 — SOLVD Health has launched a comprehensive post-approval study for AvertD®, the first U.S. Food and Drug Administration (FDA)-approved genetic test for assessing risk of developing opioid use disorder (OUD). This study aims to expand upon pivotal study findings and further demonstrate AvertD’s ability to enhance personalized data-driven decisions in real-world settings.

read more